Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia

First-line imatinib can achieve efficacy similar to that with first-line nilotinib after standardized management in accordance with the European Leukemia Network recommendations. Treatment with imatinib as first-line treatment, with a switch to nilotinib after standardized management is feasible and effective. Both nilotinib and imatinib have been shown to be well tolerated and safe.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

Publication date: Available online 12 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): O.V. Lazareva, A.G. Turkina, E.Yu Chelysheva, A.A. Kulikovsky, M.A. Galayko, O.M. Senderova, V.M. Pepeliaeva, S.V. Meresiy, A.S. Luchinin, G.I. Milutina, L.V. Gavrilova, L.B. Avdeeva, E.B. Dasheeva, O.Yu Vinogradova, H.L. Julhakyan, S.M. KulikovIntroductionRussia took part in the multicenter population-based Study (Europe) and included 6.8% adult patients (pts) with newly diagnosed chronic myeloid leukemia (CML) (Hoffman V et al. 2016).ObjectiveTo analyze the mortality in the Russian cohort of patients (pts) with new...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 27 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Xuelin Dou, Yazhen Qin, Yueyun Lai, Hongxia Shi, Xiaojun Huang, Qian JiangAbstractIntroductionTo compare the efficacy and safety of generic and branded imatinib in adults with newly diagnosed chronic myeloid leukaemia in the chronic phase (CML-CP), we retrospectively reviewed data from patients CML-CP receiving generic or branded imatinib.Patients and MethodsA propensity score matching (PSM) study was performed. Cox regression model was used to identify factors associated with responses and outcomes.Results442 adults ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionIn total, 42% of the patients experienced WS after TKI therapy discontinuation in the RU-SKI study. Physicians should be warned about the possibility of WS development, and patients of older age and with longer TKI treatment need special attention.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yilin Chen, Hua Yin, Lifeng Chen, Yingyuan Xiong, Li Meng, Jingming Guo, Haiyan Wang, Weiming LiAbstractBackgroundWe investigated the real-life choice of first-line treatment in the chronic phase of chronic myeloid leukemia (CML-CP) and the feasibility of switching to nilotinib after first-line imatinib.Patients and MethodsWe performed a retrospective analysis of the efficacy and safety of imatinib versus nilotinib as first-line therapy for patients with CML-CP. We also performed a comparative analysis of the efficacy...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 31 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jameel Al-Ghazaly, Waled Al-Dubai, Yousr Noaman, Munasser Abdullah, Leila Al-Gharasi, Gianantonio RostiAbstractBackgroundIn a developing country like Yemen, data are limited regarding the outcome of Imatinib treatment of chronic myeloid leukemia and the impact of non-adherence to Imatinib and prior duration of hydroxyurea.Patients and methodsA longitudinal cohort study, which included 164 Yemeni patients was performed. Data regarding the disease characteristics, adherence to treatment (The medication possession ratio...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yilin Chen, Hua Yin, Lifeng Chen, Yingyuan Xiong, Li Meng, Jingming Guo, Haiyan Wang, Weiming LiAbstractTo investigate the real-life choice of first-line treatment in the chronic phase of chronic myeloid leukemia (CML-CP) and the feasibility of switching to nilotinib treatment strategy after first-line imatinib. We went through retrospective analysis of the efficacy and safety of imatinib versus nilotinib for first-line for CML-CP patients, and comparative analysis of the efficacy of sustained imatinib versus switchin...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
AbstractRisk-stratification is an essential management tool in defining prognosis of haematological neoplasms, both from patient and physician perspective. We define a new prognostic term “Dynamic Response Assessment Method(s) (DRAM)” as “method(s) used for re-stratifying disease prognosis at fixed intervals during the treatment course”. The risk stratification is done after a fixed duration of treatment or chemotherapy cycles using sensitive techniques. The information obtai ned then can be used for further therapeutic decisions and prognostication. Currently, there is enough evidence that response...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
ConclusionHalving time of BCR-ABL1appears promising in prediction of outcome in CML
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study aims to evaluate the molecular response to generic Imatinib in Iranian patients with CML.MethodsThis prospective study consisted of 255 newly-diagnosed CML patients received imatinib. Molecular response was analyzed at 3 and 6 months from the start of the treatment and then every six months, and long-term outcomes included overall survival (OS ) and progression free survival (PFS) were evaluated.ResultsAt a median follow-up of 34.8 months (range: 3-84 (the OS and PFS at 7 years were 94.3% and 92.9%, respectively. Eighty-four months PFS rates in patients with a BCR-ABL IS ≤10% at 3rd months and BCR-ABLIS ≤1...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We report results of preclinical studies and clinical trials, and discuss the mechanism of action of SINEs and their effects in multiple myeloma, non-Hodgkin lymphomas, lymphoblastic leukemia, and acute and chronic myeloid leukemia. In the future, the numerous experimental studies currently underway will allow us to define the role of SINEs and will possibly permit these substances to be introduced into daily clinical practice.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Hematology | Leukemia | Lymphoma | Men | Myeloma | Nilotinib | Study | Tasigna